Lunaphore Technologies SA, a Lausanne, Switzerland-based medtech company developing a next-generation technology for cancer tissue diagnostics, closed a CHF6M second financing round.
Backers included Zühlke Ventures, Polytech Ecosystem Ventures and Occident Group, and existing investors Redalpine Venture Partners.
The company intends to use the funds for the development and market introduction of its devices.
Founded in 2014, by Dr. Ata Tuna Ciftlik, CEO, Lunaphore builds devices based on microfluidic tissue processor technology that can shorten the time of cancer diagnostics assays with high precision.
The technology has already been tested in collaboration with key opinion leaders, internationally, and in different laboratories and hospitals.